0001209191-20-005441.txt : 20200129 0001209191-20-005441.hdr.sgml : 20200129 20200129193728 ACCESSION NUMBER: 0001209191-20-005441 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200127 FILED AS OF DATE: 20200129 DATE AS OF CHANGE: 20200129 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cui Jingrong Jean CENTRAL INDEX KEY: 0001772259 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38871 FILM NUMBER: 20559461 MAIL ADDRESS: STREET 1: C/O TURNING POINT THERAPEUTICS, INC. STREET 2: 10628 SCIENCE CENTER DR., STE. 225 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Turning Point Therapeutics, Inc. CENTRAL INDEX KEY: 0001595893 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463826166 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-926-5251 MAIL ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: TP Therapeutics, Inc. DATE OF NAME CHANGE: 20181018 FORMER COMPANY: FORMER CONFORMED NAME: TP Therapeutics, INC DATE OF NAME CHANGE: 20140106 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-01-27 0 0001595893 Turning Point Therapeutics, Inc. TPTX 0001772259 Cui Jingrong Jean C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DRIVE, STE. 200 SAN DIEGO CA 92121 1 1 0 0 Chief Scientific Officer Common Stock 1301298 D Common Stock 2020-01-27 4 S 0 1599 56.82 D 867620 I By spouse Common Stock 2020-01-27 4 S 0 3800 57.71 D 863820 I By spouse Common Stock 2020-01-27 4 S 0 1601 58.40 D 862219 I By spouse Common Stock 2020-01-28 4 S 0 4068 58.1761 D 858151 I By spouse Common Stock 2020-01-28 4 S 0 2932 58.6181 D 855219 I By spouse Common Stock 2020-01-29 4 S 0 3399 58.39 D 851820 I By spouse Common Stock 2020-01-29 4 S 0 3501 59.03 D 848319 I By spouse Common Stock 2020-01-29 4 S 0 100 59.72 D 848219 I By spouse Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. The weighted average sale price for the transaction reported was $56.82, and the range of prices were between $56.20 and $57.18. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $57.71, and the range of prices were between $57.20 and $58.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $58.40, and the range of prices were between $58.20 and $58.655. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $58.1761, and the range of prices were between $57.46 and $58.45. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $58.6181, and the range of prices were between $58.46 and $58.89. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $58.39, and the range of prices were between $57.71 and $58.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $59.03, and the range of prices were between $58.71 and $59.515. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. /s/ Annette North, Attorney-in-Fact 2020-01-29